Details of the Drug Reposition

General Information of This Drug (ID: DMSD1UN)

• Drug Name: Bevacizumab (DMSD1UN)
• Synonyms: Bevacizumab (ophthalmic slow-release tissue tablet)
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

17 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lung adenocarcinoma	DISD51WR	N.A.	Approved	[1]
Colorectal carcinoma	DIS5PYL0	N.A.	Approved	[2]
Intracranial meningioma	DISD09EF	N.A.	Approved	[3]
Malignant epithelial tumor of ovary	DISBEXT0	N.A.	Approved	[4]
Esophageal disorder	DIS5L3HQ	N.A.	Approved	[5]
Hemangioblastoma	DIS1EAZC	N.A.	Approved	[6]
Colon adenocarcinoma	DISDRE0J	N.A.	Approved	[7]
Childhood acute megakaryoblastic leukemia	DIS5VZDR	N.A.	Approved	[8]
Adult acute monocytic leukemia	DISG6BLX	N.A.	Approved	[8]
Glioblastoma	DISI0V5E	2A00	Approved	[9]
Rectal adenocarcinoma	DIS8R9VO	2B92	Approved	[10]
Cholangiocarcinoma	DIS71F6X	2C12.10	Approved	[11]
Biliary tract cancer	DISBNYQL	2C17	Approved	[12]
Non-small-cell lung cancer	DIS5Y6R9	2C25.Y	Approved	[13]
Adenocarcinoma	DIS3IHTY	2D40	Approved	[14]
Von hippel-lindau disease	DIS6ZFQQ	5A75	Approved	[15]
Metastatic colorectal cancer	DIS18R3K	2B91	Approved	[16]

1 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 2/3	[17]

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1	[18]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Peritoneal cancer	DISYX23I	2C51.Z	Withdrawn	[19]

1 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Carcinoma of esophagus	DISS6G4D	N.A.	Discontinued in Phase 3	[20]

7 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Metastatic malignant neoplasm in the colon	DISO31AF	N.A.	Discontinued in Phase 2	[21]
Neoplasm of esophagus	DISOLKAQ	N.A.	Discontinued in Phase 2	[22]
Colorectal neoplasm	DISR1UCN	N.A.	Discontinued in Phase 2	[23]
Brain neoplasm	DISY3EKS	N.A.	Discontinued in Phase 2	[24]
Cervical carcinoma	DIST4S00	N.A.	Discontinued in Phase 2	[25]
Renal cell carcinoma	DISQZ2X8	2C90	Discontinued in Phase 2	[26]
Metastatic melanoma	DISSL43L	2E2Z	Discontinued in Phase 2	[27]

1 Application submitted Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian cancer	DISZJHAP	2C73	Application submitted	[18]

5 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lung large cell carcinoma	DISUG64F	N.A.	Investigative	[28]
Adult glioblastoma	DISVP4LU	N.A.	Investigative	[29]
Colon cancer	DISVC52G	2B90.Z	Investigative	[30]
Fallopian tube cancer	DISXHWCS	2C74	Investigative	[31]
Hereditary hemorrhagic telangiectasia	DISXTDNT	LA90.00	Investigative	[32]

References

• [1] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85.
• [2] Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508.
• [3] The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203.
• [4] Gynecologic cancer in pregnancy. Gynecol Oncol. 2020 Jun;157(3):799-809.
• [5] Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):229.
• [6] Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma. Cureus. 2022 Dec 17;14(12):e32624.
• [7] Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. Immunotherapy. 2023 Feb;15(3):127-133.
• [8] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [9] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
• [10] Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as?preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term?results. BMC Cancer. 2020 Nov 27;20(1):1164.
• [11] Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565.
• [12] Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021 Apr;30(4):411-418.
• [13] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.
• [14] Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. Rare Tumors. 2019 May 14;11:2036361318825413.
• [15] 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. J Nucl Med. 2016 Aug;57(8):1244-50.
• [16] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [17] ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
• [20] Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)
• [21] A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.
• [22] Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
• [23] Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
• [24] ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
• [25] ClinicalTrials.gov (NCT01020305) Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
• [26] Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
• [27] Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
• [28] Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.
• [29] Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963.
• [30] Colon cancer. Crit Rev Oncol Hematol. 2010 May;74(2):106-33.
• [31] OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.
• [32] Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 Sep;103(9):1433-1443.